“This systematic review aims to integrate the evidence on indications, efficacy, safety and pharmacokinetics of medical cannabinoids in older subjects…
Although trials studying medical cannabinoids included older subjects, there is a lack of evidence of its use specifically in older patients. Adequately powered trials are needed to assess the efficacy and safety of cannabinoids in older subjects, as the potential symptomatic benefit is especially attractive in this age group.”
“We hypothesized that the endocannabinoid (EC) system, a neuromodulatory system intrinsic to the cortical microcircuitry, is an important regulator of up-states and sleep…
Overall, these findings demonstrate that the EC system actively regulates cortical up-states and important features of NREM sleep such as its duration and low frequency cortical oscillations.”
“This unit describes the use of cannabinoid radioligands in competitive binding assays for determining affinity parameters (IC50 , Ki ) of unlabeled compounds at transfected CB1 and CB2 receptors expressed in cell lines.”
“Blood coagulation studies were conducted to determine the possible anti-/prothrombotic effect of an organic cannabis extract and the three major cannabinoids, THC, CBD and CBN…
The study thus shows that Cannabis sativa and the cannabinoids, THC and CBN, display anticoagulant activity and may be useful in the treatment of diseases such as type 2 diabetes in which a hypercoagulable state exists.”
“Kaercher said no matter what treatments Grace is on, the seizures continue. She has tried every option except medical marijuana, which isn’t legal in Pennsylvania,
Kaercher said. “Marijuana isn’t that extreme compared to all these other things we have done,” Kaercher said. Kaercher, 45, has watched her daughter suffer from seizures since Grace was a baby. Kaercher said Grave is so brave for going out into the world every day and her heart breaks every time Grace has a seizure.“It’s been a long road for us,” Kaercher said. “We hope medical marijuana will be a viable option for her.””
“Hunger arouses sensory perception, eventually leading to an increase in food intake, but the underlying mechanisms remain poorly understood. We found that cannabinoid type-1 (CB1) receptors promote food intake in fasted mice by increasing odor detection.
CB1 receptors were abundantly expressed on axon terminals of centrifugal cortical glutamatergic neurons that project to inhibitory granule cells of the main olfactory bulb (MOB).
Local pharmacological and genetic manipulations revealed that endocannabinoids and exogenous cannabinoids increased odor detection and food intake in fasted mice by decreasing excitatory drive from olfactory cortex areas to the MOB.
Consistently, cannabinoid agonists dampened in vivo optogenetically stimulated excitatory transmission in the same circuit.
Our data indicate that cortical feedback projections to the MOB crucially regulate food intake via CB1 receptor signaling, linking the feeling of hunger to stronger odor processing.Thus, CB1 receptor-dependent control of cortical feedback projections in olfactory circuits couples internal states to perception and behavior.”
“Here, we sought to assess the effects of natural and synthetic cannabinoids on cholinergic bronchial contraction…
Delta-9-tetrahydrocannabinol, WIN55,212-2 and CP55,940 induced concentration-dependent inhibition of cholinergic contraction…
Activation of prejunctional CB1-receptors appears to mediate the inhibition of electrical field stimulation-evoked cholinergic contraction in human bronchus.
This feature may explain the acute bronchodilation produced by marijuana smoking.”
http://onlinelibrary.wiley.com/doi/10.1111/bph.12597/abstract
“The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer’s disease (AD).
…The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.”
“Cannabinoids have been demonstrated to exert neuroprotective effects on different types of neuronal insults.
Here we have addressed the therapeutic potential of the synthetic cannabinoid HU210 on photoreceptor degeneration, synaptic connectivity and functional activity of the retina in the transgenic P23H rat, an animal model for autosomal dominant retinitis pigmentosa (RP)…
These data suggest that cannabinoids are potentially useful to delay retinal degeneration in RP patients.”
“Increasing evidence from preclinical studies supports the interest of the endocannabinoid system as an emerging therapeutic target for osteoarthritis pain.
Indeed, pharmacological studies have shown the anti-nociceptive effects of cannabinoids in different rodent models of osteoarthritis, and compelling evidence suggests an active participation of the endocannabinoid system in the pathophysiology of this disease.
The ubiquitous distribution of cannabinoid receptors, together with the physiological role of the endocannabinoid system in the regulation of pain, inflammation and even joint function further support the therapeutic interest of cannabinoids for osteoarthritis.
…review summarizes the promising results that have been recently obtained in support of the therapeutic value of cannabinoids for osteoarthritis management.”